XSHE
300138
Market cap822mUSD
Oct 09, Last price
11.82CNY
1D
3.68%
1Q
20.49%
Jan 2017
27.08%
IPO
47.37%
Name
Chenguang Biotech Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ChenGuang Biotech Group Co., Ltd. is a key player in the development and production of natural ingredients. Its extensive product catalog encompasses natural colorants, including paprika and marigold oleoresins, as well as turmeric. The company also manufactures a diverse array of spice extracts and essential oils, such as capsicum oleoresin, Sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oil. Furthermore, ChenGuang Biotech provides a variety of nutritional and pharmaceutical extracts like lutein, lycopene, grape seed extract, curcumin, inulin, stevioside, and green coffee bean extracts. Rounding out its offerings are various oils and protein products, specifically grape seed, walnut, safflower, flaxseed, and cottonseed oils, alongside natural lutein and dephenolized cottonseed protein. These versatile ingredients are widely utilized across sectors such as food, beverages, cosmetics, baking, healthcare, and animal feed. Established in 2000 and based in Quzhou, China, the company has a global operational footprint, serving customers across Europe, the Americas, Australia, Asia (including China, Russia, Japan, and Korea), and Africa.
Key people
Qingguo Lu
Chairman of the Board · since 2025
Ying Lu
General Manager, Director · since 2025
Fengfei Li
Deputy General Manager · since 1999
Yunhe Lian
Deputy General Manager
Jing Zhou
Finance Director, Deputy General Manager, Company Secretary, Director · since 2023
Tao Zhao
Staff Elected Director · since 2025
Xiaofeng Dai
Independent Director · since 2023
Liangqiu Li
Independent Director · since 2023
Hong Niu
Independent Director · since 2023
Headquarters & legal address
河北省邯郸市曲周县晨光路1号
邯郸市, HE 100000
CN
邯郸市, HE 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2021‑00 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||